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Abstract 
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive disease which 
leads to systemic disease, including progressive neurodegeneration, mental 
retardation and death before the age of 10 years. MPS I results from deficiency 
of α-L-iduronidase (IDUA) and subsequent accumulation of glycosaminoglycans 
(GAG). IDUA enzyme acitivity is an essential assessment for research and 
diagnostic testing of MPS I disease. Due to different parameters (reaction time, 
temperature and substrate concentration) used by different labs, the enzyme 
levels of a certain sample varied. To solve the inconsistency of IDUA enzyme 
assays in this field, a standardized protocol of IDUA enzyme assay was 
established through adjustment by Michaelis-Menten equation (Chaper 1). In 
clinical practice, MPS I disease is treated by enzyme replacement therapy (ERT) 
and bone marrow transplantation (BMT). Clinical ERT with intravenous IDUA 
reverses some aspects of MPS I disease and ameliorates others. However, 
neurologic benefits are thought to be negligible because the blood-brain barrier 
(BBB) blocks enzyme from reaching the central nervous system (CNS). To 
address this question, high-dose IDUA (11.6 mg/kg, once per week, 4 weeks) 
was administered to adult MPS I mice. IDUA enzyme activity in cortex of injected 
mice increased to 97% of that in wild type mice (p<0.01). GAG levels in cortex 
were reduced by 63% of that from untreated MPS I mice (p<0.05). Water T-maze 
tests showed that the learning abnormality in MPS I mice was surprisingly 
reduced (p<0.0001). These results demonstrated the efficacy of high dose ERT 
in treating neurological diseases in MPS I mice (Chapter 2). Previous study in our 
lab showed that a single administration of lentiviral vector in neonatal MPS I mice 
can achieve significant metabolic correction and neurological improvements. To 
further improve the efficacy of lentiviral gene therapy, a total of 9 constructs were 
designed by codon optimization, and different combination of promoters and 
enhancers. The transgene expression of these 10 constructs was compared after 
transfection into HEK 293FT cells, and 5 constructs with the highest IDUA 
expression were identified (Chapter 4). These results pave the way for 
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developing a directly applicable clinical trial of human lentiviral gene therapy for 
MPS I disease, and also provide evidence for vector design for treating other 
lysosomal diseases. 
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1. Overview 
The mucopolysaccharidoses (MPSs) are a group of inherited metabolic disorders, 
which belong to the large family of more than 40 identified lysosomal diseases 
(1). MPSs are caused by mutations in genes encoding lysosomal enzymes, 
which can degrade glycosaminoglycans (GAGs, formerly called 
mucopolysaccharides), long chain of sugar carbohydrates. Based on the types of 
deficient enzyme and accumulated GAGs, 11 types and subtypes of MPS 
diseases have been distinguished. 
 
Deficiency of these enzymes can lead to subsequent lysosomal accumulation of 
GAG storage materials (2-5). This causes progressive tissue damage, and 
thereby severe dysfunction of various organs, including heart, lung, bone, joint, 
and central nervous system (CNS). The major symptoms of MPS diseases 
include cardiopulmonary disease, growth delay, skeletal dysplasias, 
organomegaly and shortened lifespan. Moreover, patients with severe MPS I, II, 
III, and VII exhibit progressive neurodegeneration and mental retardation. 
 
Current available therapies for treating the MPS diseases include hematopoietic 
stem cell transplantation (HSCT) and enzyme replacement therapy (ERT). 
However, HSCT has a high rate of mortality (10-15%) and severe morbidity. ERT 
is of limited use due to the need for frequent, life long, and expensive (>$200,000 
per year) treatments. Further, ERT has negligible neurological improvements 
because the blood-brain-barrier (BBB) prevents the intravenously infused 
enzyme from entering the brain. 
 
1. Description of MPS diseases 
2.1 MPS I 
MPS I is associated with an incidence of approximately 1 out of 100,000 and 
results from mutations in gene encoding the lysosomal enzyme α-L-iduronidase 
(IDUA) (5-7). Deficiency of IDUA gives rise to progressive lysosomal 
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accumulation of heparan and dermatan sulfate in tissues (5). The symptoms of 
MPS I start to manifest in the childhood. Based on the severity of symptoms, 
MPS I can be divided into three subtypes, from severe (Hurler syndrome) to 
intermediate (Hurler-Scheie syndrome) to mild (Scheie syndrome) (5, 6). Patients 
with Scheie or Hurler-Scheie diseases have symptoms including growth delay, 
aortic valvular disease, skeletal dysplasias, corneal clouding and joint stiffness 
(5). In addition to more severe forms of these symptoms, patients with Hurler 
syndrome also have growth delay, hepatosplenomegaly, unique facial features, 
hydrocephalus, mental retardation and neurodegeneration. Moreover, Hurler 
syndrome patients usually die before the age of 10 years old. ERT with 0.58 
mg/kg of laronidase (Aldurazyme) per week has been available for patients and 
can treat non-neurological symptoms of MPS I patients. Also, HSCT has 
demonstrated its efficacy in treating some aspects of Hurler syndrome (7). 
 
2.2 MPS II 
MPS II (Hunter syndrome) is caused by deficiency of the enzyme iduronate-2-
sulfatase (IDS) and subsequent lysosomal accumulation of heparan and 
dermatan sulfate (5). MPS II has an X-linked recessive inheritance, with an 
incidence of approximately 1 out of 150,000 (8, 9).  
 
The initial symptoms of MPS II include ear infections, abdominal and hernias that 
are quite common to babies, making it more difficult for early diagnosis. Within 
the first 2 years, most MPS II patients begin to exhibit growth delay, hearing loss, 
coarse facial features, cardiovascular problems, respiratory problems, and 
neurocognitive disabilities (10-12). Similarly, MPS II can be divided into two 
subtypes based on the severity of symptoms: mild and severe. The severe form 
is usually associated with neurodegeneration and death within less than 15 years, 
while some patients with the mild form can survive up to their 50s or 60s. ERT 
with idursulfase has been shown to provide MPS II patients metabolic correction. 
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2.3 MPS III 
MPS III (Sanfilippo syndrome) is a rare autosomal recessive lysosomal disease, 
which is caused by deficiency in one of the enzymes degrading GAG heparan 
sulfate. The incidence of MPS III is approximately 1 out of 70,000. MPS III can be 
divided into 4 subtypes based on deficiency of different enzymes: Sanfilippo 
syndrome types A, B, C, and D (5). The 4 different enzymes responsible for 
degradation of GAGs are listed as followed: heparan sulfate sulfamidase (SGSH), 
α-N-acetylglucosaminidase (NAGLU), N-acetylglucosamine 6-sulfatase (GNS) 
and heparan sulfate acetyl-CoA: α-glucosaminide N-acetyltransferase (HGSNAT). 
In spite of the differences in nature of enzymes, the clinical manifestations of the 
4 subtypes are almost indistinguishable. Among all MPS diseases, MPS III has 
the mildest physical symptoms, only including hearing loss, coarse facial features, 
heptatomegaly and umbilical hemia (13, 14). Also, patients with MPS III can 
usually live into adolescence or early adulthood. However, MPS III disease is 
usually associated with severe neurological manifestations. Currently, there is no 
available ERT for MPS III disease, and the treatment remains largely supportive. 
 
2.4 MPS IV 
The incidence of MPS IV (Morquio syndrome) is estimated to be 1 out of 200,000 
to 300,000. MPS IV can be divided into two subtypes based on the deficient 
enzymes galactose 6-sulfate sulfatase (Type A) and beta-galactosidase (Type B), 
which are responsible for degrading the keratan sulfate sugar chain. Clinical 
manifestations of these two subtypes are similar, however, Type B is usually 
associated with milder symptoms. Patients with MPS IV usually appear healthy at 
birth, which makes it difficult for early diagnosis. The symptoms of MPS IV 
include abnormal heart and skeletal development, hypermobile joints, bell-
shaped chest, spinal cord compression and short stature. Unlike other MPS 
diseases, MPS IV does not affect intelligence and neurocognitive abilities. 
Patients with MPS IV usually can live into late childhood, and some with mild 
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disease may survive into their 70s. Currently, ERT with elosulfase alfa (VIMIZIM) 
has been available for MPS IV patients. 
 
2.5 MPS VI 
MPS VI (Maroteaux-Lamy syndrome) results from deficiency of arylsulfatase B 
(ARSB) (15, 16), and subsequent lysosomal accumulation of dermatan sulfate 
and sulfated oligosaccharides. MPS VI has a wide spectrum of severity, which is 
based on the amount of residual ARSB activity. MPS VI patients share similar 
symptoms with Hurler syndrome, but do not have abnormal intellectual 
development. The onset of MPS VI disease is early in life, with one of the initial 
symptoms being a prolonged period of learning how to walk. Most patients have 
severe skeletal abnormalities, including short stature, joint stiffness and spinal 
stenosis. In terms of the lifespan, MPS VI patients typically die due to cardiac 
malfunction in early adulthood (5). Currently, ERT with galsulfase (Naglazyme) 
has been available for MPS VI patients and has successfully achieved 
improvements in growth and joint movements. 
 
2.6 MPS VII 
MPS VII (Sly syndrome) is an autosomal recessive inherited disease due to 
deficiency of ß-glucuronidase (GUSB) activity and subsequent lysosomal 
accumulation of heparan sulfate, dermatan sulfate, and chondroitin sulfate. The 
incidence of MPS VII is approximately 1 out of 250,000. MPS VII shares similar 
features with MPS I disease. Mild patients exhibit hepatosplenomegaly and 
skeletal dysplasias without intellectual impairments, and can even survive into 
their 50s (5). Patients with more severe MPS VII disease usually have 
hepatosplenomegaly, corneal clouding, dysostosis multiplex, mental retardation, 
coarse facial features, hearing loss and early death. 
 
2.7 MPS IX 
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MPS IX (Natowicz syndrome) is caused by mutations in the gene encoding 
hyaluronidase (17, 18). The deficiency of active hyaluronidase leads to lysosomal 
accumulation of hyaluronan. Up to 2001, only one MPS IX patient has been 
reported. The symptoms of MPS IX include painful swelling of the masses, 
growth delay, and coarse facial features. No neurological impairments have been 
identified with MPS IX disease. 
 
2. Molecular biology of MPS diseases 
GAGs are long unbranched polysaccharides consisting of repeating disaccharide 
units of an acidic sugar (uronic or iduronic acid) and an N-acetylated amino sugar. 
Based on type of sugars and linkeage, number and location of sulfate groups, 
GAGs can be classified into several types: hyaluronic acid/hyaluronan, 
chondroitin sulfate, keratan sulfate, dermatan sulfate, heparin and heparan 
sulfate. GAGs are essential components of extracellular matrix and can provide 
tissues with resilence under pressure. For degradation, extraceullar GAGs are 
endocytosized into cells, transported to lysosomes and broken down by specific 
enzymes. Deficiency of enzyme involved in GAG degradation leads to lysosomal 
diseases (see details in Figure 1). 
 
Lysosomal enzyme is synthesized in the endoplasmic reticulum (ER), and 
mannose and mannose 6-phosphate (M6P) residues are added in the Golgi 
apparatus. Approximately 90 % of enzyme is targeted to lysosome by mannose 
6-phosphate receptors (M6PRs), while the rest is secreted and endocytosed 
mainly by ubiquitously distributed M6PRs and mannose receptors (MRs) on 
macrophages (19, 20). Deficiency of enzyme adding M6P residues to lysosomal 
enzyme leads to inclusion-cell (I-cell) disease. Without M6P residues, lysosomal 
enzyme cannot be targeted to lysosomes, and are instead secreted out of cells. 
Therefore, lysosome cannot function normally to degrade sustances (e.g. 
oligosaccharides, lipids, and glycosaminoglycans), resulting in characteristic 
‘inclusion cells’. The I-cell phenotype is also observed when IDUA is 
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overexpressed (up tp 250 fold of normal levels) by retroviral vector transduction 
into cells. It may result from saturation of M6P mediated lysosome-targeting 
pathway by high level of IDUA, which leads to reduced amount of other enzymes 
delivered to lysosome(21). These results suggest that when treating lysosomal 
diseases with gene therapy, transgene expression should be controlled within 
certain limits because extremely high levels of one enzyme may induce the ‘I-cell’ 
like phenotype.  
 
Lysosomal enzyme delivery across the BBB in neonatal mice is through M6PRs, 
which are down-regulated after first two weeks of life in mice (22). Therefore, it is 
extremely difficult to treat the CNS pathology of MPS diseases after the neonatal 
period. However, it has been shown in MPS VII that when mannose and M6P 
residues were eliminated from the lysosomal enzyme, plasma half-life was 
dramatically prolonged from 11 minutes to 18.5 hours (23). Also, enzyme 
diffusion was more efficient, manifested by the wide spread GAG storage 
reduction in multiple organs including brain (23). Although the mechanism of how 
these enzymes targeted to the lysosome remains unclear, the therapeutic 
benefits are significant and not exclusive to the CNS. Also, when blocking the 
MR-mediated clearance system by knocking out MR, or by infusing competitive 
inhibitors of mannose, wider distribution and enhanced clearance of storage in 
other difficult-to-reach sites for enzyme, e.g. bone and retina, was observed (20). 
Although neither knocking out ubiquitously expressed MR nor using toxic MR 
inhibitors is feasible in human patients, making mutant enzyme that cannot be 
bound by MR might be a good choice to achieve better enzyme diffusion. 
 
3. Neuropathology of MPS diseases 
Patients with severe MPS I, II, III, and VII exhibit neurological impairments. 
Currently, the mechanism of neurological disease is not well understood. 
Accumulation of GM2 and GM3 gangliosides in brain has been identified (24-28), 
suggesting their potential roles in neurological pathogenesis.  
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GM2 and GM3 gangliosides have been shown to be upregulated in several types 
of MPS diseases (29, 30). Although the mechanism how GM2 and GM3 
contribute to neuropathogenesis is not elucidated, it has been related with altered 
synaptic connectivity and reinitiation of dendrite growth (31). In addition, 
overexpression of GM3 synthase can lead to reactive oxygen species (ROS) 
production and even death of neuronal cells (32). Also, it has been suggested 
that cell signaling, apoptosis, astrogliosis inflammation and oxidative damage 
may be involved (33). Astrogliosis were identified in brain of MPS III patients, 
which was consistent with the fact that inflammatory pathways were upregulated 
by inhibiting macrophage migration inhibitor factor (Mif) (35, 36). More 
interestingly, there is evidence that some signaling pathways may contribute to 
the neuropathogenesis of MPSs. Fibroblast growth factor 2 (FGF-2) is a cytokine 
involved in tissue neurogenesis and morphogenesis (37), which can also 
promote neuronal survival (38). When incubated with FGF-2, multipotent adult 
progenitor cells (MAPCs) can differentiate into neurons and glia cells (39). 
Abnormal heparan sulfate molecules have been shown to interfere with 
interactions between FGF-2, FGF receptors, and heparan sulfate molecules. 
Furthermore, these abnormal interactions can reduce proliferation and survival of 
MAPCs (34). In light of these facts, the perturbation of heparan sulfate and FGF 
interaction may play a role in neuropathogenesis of MPS diseases. In addition, it 
has been shown that apoptosis may contribute to the neuropathology of MPS IIIB 
(35). Collectively, the mechanisms of neurological impairments in MPS I, II, III, 
and VII have not been elucidated, and remain a heated topic in this field.  
  
4. Current Therapies 
Treatment of MPSs is mainly based on the phenomenon of cross-correction: 
lysosomal enzyme infused or secreted from transduced cells reaches other 
tissues through blood circulation (40). This is possible because approximately 
10% of the lysosomal enzymes produced in a cell will be secreted and 
recaptured by other cells. Circulating lysosomal enzymes are mainly taken up by 
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cells via M6PRs and/or MRs (41). Therefore, only a relatively small number of 
cells expressing the lysosomal enzyme are sufficient to correct many other cells 
(42). Besides the efficiency of receptor-mediated endocytosis, cross-correction 
depends on the efficiency of secretion of lysosomal enzymes from the cells in 
which they are produced (43).  
 
Although extensive studies on developing novel therapies for MPS diseases 
have been conducted, only a couple of therapeutic options are available to 
patients. Currently, there are HSCT and ERT for treating MPS diseases. Further, 
gene therapies or small molecule therapies are under development and will 
potentially be applied in clinical trials. 
 
4.1 Enzyme Replacement Therapy 
ERT is intravenously administering human recombinant lysosomal enzyme into 
patients. Currently, ERT is available for only three MPS types: I, II and VI (44, 45). 
It seems that the results of ERT depend on the severity of disease at the onset of 
treatment. Generally, following treatment with ERT, patients exhibit decrease in 
urine GAG levels, resolution of hepatoslenomegaly, and cardiopulmonary 
improvements as shown by 6 minute walk test (6MWT) within the first 6 months 
of treatment (46).  
 
However, more than 50% of patients treated with ERT develop antibodies to the 
recombinant proteins. ERT is of limited use due to the need for frequent, life long, 
and expensive (>$200,000 per year) treatments. Further, ERT has negligible 
neurological improvements because the BBB prevents the intravenously infused 
enzyme from entering the brain (47-52). 
 
In terms of neurological improvements, intrathecal ERT has provided promising 
results, especially for treating spinal cord compression (53, 54). Following 
intrathecal infusion of IDUA into MPS I dogs, high levels of IDUA activity and 
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GAG reduction have been observed in the spinal, cervical, and lumbar meninges. 
Furthermore, in MPS I dogs, infusion of IDUA into the cisterna magna resulted in 
reduction of storage material in glia, perivascular cells, and neurons (49, 55). 
However, these studies were limited to animal, adult or non-neuronopathic 
pediatric patients. In light of this, it is essential to investigate whether intrathecal 
ERT can be safely applied in MPS children. 
 
Intrathecal ERT has been conducted in MPS I dogs and successfully reduced 
GAGs in the CNS (55, 57).The rationale of intrathecal ERT is that in the 
cerebrospinal fluid (CSF), a small amount of the lysosomal enzyme can 
represent large concentration gradients when compared with the affinity 
constants for the enzyme receptors on neurons, glia and other cells. In light of 
the very large concentration gradients, a tiny amount of enzyme can penetrate 
the ependymal layer and result in sufficient uptake by neurons and glia at the end 
sites. 
 
4.2 Hematopoietic Stem Cell Transplantation 
It has been shown that MPS diseases can be treated by HSCT. The underlying 
mechanism might be that donor-derived HSCs differentiate into macrophages in 
spleen and lung, Kupffer cells in liver, and microglial cells in brain (57, 58). The 
donor-derived cells then can provide enzyme to deficient cells via metabolic 
cross-correction. Untill now, there are no randomized controlled trials (RCT) with 
BMT or HSCT for MPS diseases, therefore, our discussion here will be mainly 
based on anecdotal descriptions. In 1980, the first BMT for the treatment of MPS 
disease was performed on a child with MPS I (59). Since then, approximately 
500 children have received transplantation for MPS I, II, III, IV, VI, and VII (60). 
Stabilization of the disease or deceleration of the disease progress was 
successfully achieved in patients. However, it has been suggested that some 
MPS diseases, like MPS III, are generally significantly less responsive to BMT or 
HSCT (61). Moreover, good timing is essential for achieving significant 
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improvements in patients, effective treatment for MPS I disease can be achieved 
when transplantation was performed in patients below 2.5 years old of age (62). 
 
Prior to transplantation, patients usually receive treatment with 
cyclophosphamide and either busulphan or total body irradiation (63-65) to 
create space for engraftment. In Hurler syndrome, it seems that success of 
engraftment depends on cell dose (65, 66-68). In addition to graft rejection, which 
decreases the rate of long term survival following treatment, patients are also 
subject to HSCT-related mortality due to graft-versus-host disease (GVHD), 
sepsis, or pneumonia. The rate of GVHD was reported to be between 35% and 
50% while the mortality rate due to transplant complications is between 11% and 
45% (63, 67). As relevant procedures have been improved and wide use of cord 
blood, risk for these complications has gradually decreased. 
 
Several months after transplantation, there are improvements in spleen, liver, 
lung and upper respiratory system. Also, improvements in hydrocephalus and 
neurocognitive disability have been reported in many patients after 
transplantation. Moreover, symptoms in growth, corneal clouding and 
development of the musculoskeletal system were at least partially reduced, and 
improvements in joints and hearing were observed in many patients. Also, 
although cardiac valve deformities still persist, there is a significant decrease in 
cardiac hypertrophy (60). More importantly, after transplantation, overall survival 
(OVS) rate of Hurler syndrome patient ranges from 50 to 85%, and some patients 
can live into their 30s. The age of treatment and severity of diseases is important 
for neurological outcomes of transplantation (63, 66, 68). Earlier treatment is 
more beneficial for reduction in GAG and secondary storage materials GM2 and 
GM3 ganglioside within brain (27). However, most patients still continue to 
display low IQ and neurocognitive disability after transplantation (69, 70). 
 
4.3 Small molecules 
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4.3.1 Substrate reduction therapy 
Substrate reduction therapy (SRT) offers a novel strategy for treating MPS 
diseases. Failure of relevant metabolic pathways leads to accumulation of the 
substrate (GAG) and MPS diseases. SRT solves this problem by reducing the 
level of substrate to a point where residual degradative activity is sufficient to 
prevent substrate accumulation. It was naturally expected that a decrease in 
efficiency of GAG synthesis might lead to deceleration of the storage process 
and improvements in cellular functions (71). In the optimal condition, SRT could 
restore the balance between GAG synthesis and degradation. In fact, SRT has 
been introduced as a therapeutic option for treating other lysosomal diseases, for 
instance, Gaucher disease (72) or Niemann-Pick C disease (73). Miglustat (N-
butyldeoxynojirimycin), the inhibitor of glucosylceramide synthase, has been 
applied as a drug for the aforementioned diseases. Since it can decelerate 
glycosphingolipids synthesis, miglustat is expected to be effective in reducing 
glycosphingolipids storage. In spite of accumulatiing evidence that positive 
effects of miglustat treatment in clinical trials (74, 75), its efficacy in Gaucher 
disease remains to be well defined (76). As to MPS diseases, there are various 
ways to inhibit GAG synthesis, with the most straightforward method using 
specific chemical inhibitors of GAG synthesis. However, identification of non-toxic 
inhibitors of enzymes involved in GAG synthesis is extremely difficult. Therefore, 
a search for indirect inhibitors of GAG synthesis has been conducted (77). 
Rhodamine B, a staining fluorescent dye, has been shown to decelerate GAG 
synthesis indirectly of MPS IIIA and MPS VI cells in vitro (78).  
 
Epidermal growth factor (EGF), when bound by its specific receptor, can initiate a 
signal transduction pathway leading to expression of certain genes that encode 
enzymes responsible for GAG synthesis. Genistein, a natural isoflavone, can 
interfere with this pathway by inhibiting phosphorylation of EGFR (79). Therefore, 
genistein can significantly inhibit GAG synthesis of MPS I, MPS II, MPS IIIA and 
MPS IIIB fibroblasts in vitro (79-82). Silencing the expression of genes encoding 
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GAG synthetases is another option to reduce the efficiency of GAG production. 
Currently, several strategies employing the RNA interference (RNAi) mechanism 
have been developed. For instance, short interfering RNA (siRNA) 
oligonucleotides were used to reduce mRNA levels of four genes including 
GALTI, GALTII, XYLT1 and XYLT2, whose products are responsible for GAG 
synthesis (83). Additionally, short hairpin RNA (shRNA) molecules, targeting 
EXTL2 and EXTL3 genes, whose expression was also required for GAG 
synthesis, have been employed.  
 
4.3.2 Enzyme chaperone 
Under physiological conditions, chaperones restore the native conformation of 
misfolded proteins. It has been estimated that approximately 30% of proteins 
misfold and/or aggregate, and are rapidly degraded (84). In MPS diseases, 
missense mutations and in-frame deletions may cause polypeptide misfolding, 
however, they may not or only slightly affect the functionally essential domains of 
the enzyme. This offers a chance to use pharmacological chaperones to facilitate 
the stabilization of misfolded proteins and thus treat MPS diseases. 
 
Adding N-(n-nonyl) deoxynojirimycin (NN-DNJ) to fibroblasts from a Gaucher 
patient resulted in a 2-fold increase in the enzyme activity of glucocerebrosidase 
(10). Another chaperone, 1-deoxygalactonojirimycin, was added to Fabry 
fibroblasts with missense mutations. After treatment for over 100 days, there was 
a remarkable reduction of GB3 storage (85). In GM2-gangliosidosis (Tay–Sachs 
and Sandhoff disease), the chronic adult forms have approximately 5% of normal 
enzyme activity, while some unaffected individuals have only 10% of normal 
levels. Interestingly, almost all disease-associated missense mutations do not 
affect the active sites but only cause retention and accelerated degradation. By 
adding hexosaminidase inhibitors to cultured fibroblasts from an adult GM2-
gangliosidosis patient, a significant increase in the level of hexosaminidase A 
could be achieved (86). Collectively, small molecule chaperones can be effective 
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for treating various lysosomal disorders caused by mutated but yet catalytically 
active enzymes. 
 
4.4 Gene Therapy 
Gene therapy is the most promising strategy for treating MPS diseases because 
some vectors can transduce or transfect a variety of tissues after a single 
systemic administration (87). Further, gene therapy offers the possibility of 
comprehensive and affordable treatment of all aspects of MPS diseases. 
However, on the one hand, viral vectors have drawbacks including expense and 
ease of manufacturing (88).On the other hand, non-viral vectors are limited of 
use by their inability to efficiently enter cells and penetrate the BBB. 
 
Many preclinical studies have been conducted to investigate the efficacy of gene 
therapy vectors to treat MPS diseases. Both non-viral and viral vectors have 
been employed in these studies, which include minicircles, Sleeping Beauty (SB) 
transposons, retroviruses, lentiviruses, adenoviruses and adeno-associated 
viruses (AAV). Also, different routes of administration have been investigated 
including ex vivo transduction and in vivo infusions through intravenous, 
intrathecal, intraparenchymal, intracisternal and hydrodynamic injections. 
 
4.4.1 Non-viral methods 
Two non-viral gene therapy strategies have been tested in mouse models of 
MPS diseases. The first is transposons, e.g. the SB transposon system, which 
can provide sustained transgene expression in mammalian cells (89-91). The SB 
transposon system is a plasmid-based gene transfer system, which was 
constructed by engineering of extinct DNA sequences found in salmonid fish (89, 
90, 92). The transposon and SB transposase are the main component of the SB 
system. And the transposon is composed of around 230 bp inverted repeat/direct 
repeat sequences (IR/DRs) and expression cassette encoding the gene of 
interest (GOI) with promoter sequence. When delivered into host cells, with the 
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help of IR/DRs, SB transposase can excise the transposon from the plasmid 
vector. Then, the excised transposon can randomly integrate into the host 
genome (88), allowing for stable, long-term transgene expression. Compared 
with viral vector, the advantages of using the SB transposon system for gene 
therapy include the cheap expense, ease of use, lessimmunogenicity, low risk of 
contamination with replication-competent viruses, and large capacity (88). 
However, although no adverse events have been identified, there is still concern 
about insertional mutagenesis. The SB gene therapy has been shown to be 
effective in mouse models of MPS I and MPS VII (93, 94). 
 
Another potential nonviral vector is minicircles, which are circular DNA molecules 
only containing the transgene expression cassette by removal of most plasmid 
backbone sequences (95, 96). Minicircles can provide sustained episomal 
transgene expression, successfully avoiding safety concern about insertional 
mutagenesis. The disadvantage of minicircles is that episomes are not 
necessarily carried to the daughter cells after cell divisions. Currently, minicircles 
have been employed to treat MPS I in mice (97).  
 
However, non-viral vectors cannot effectively transduce cells in the CNS, 
regardless of the administration routes. In light of this, gene therapy with 
minicircles cannot treat neurological diseases of MPSs. 
 
4.4.2 Viral gene therapy 
4.4.2.1 Retrovirus 
Retroviruses are a group of viruses with two identical strands of RNA as genetic 
materials. The retroviral genome contains three genes, gag, pol, and env, which 
encode proteins necessary for viral life cycle. These sequences are flanked by 
long terminal repeats (LTRs) responsible for reverse transcription and integration.  
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The pol gene encodes reverse transcriptase, which can produce a double 
stranded DNA (dsDNA) copy of the viral RNA genome (98) upon entry into host 
cells. After converted into dsDNA and transported to the nucleus, the viral DNA 
can integrate into the host genome with the help of the viral integrase. 
Transcription and translation of the integrated viral gene sequence by the host 
cell machinery can lead to production of viral genomes and proteins for 
completing the viral life cycle. For gene therapy application in MPS diseases, 
retroviral vectors have been engineered by replacing the gag, pol and env genes 
by a gene encoding a therapeutic lysosomal enzyme. After integration of the 
therapeutic gene into the host genome, long-term transgene expression can be 
achieved in target cells.  
 
Retroviruses were the first vectors used for gene therapy of MPS diseases (99). 
Due to safety concern about insertional mutagenesis, self-inactivating 
retroviruses (SIN-RVs) were thereby designed (100, 101). SIN-RVs achieved 
lower levels transgene expression and were less efficient in correcting clinical 
symptoms, however, this can be overcome by increasing the dose. However, 
retrovirus gene therapy is still with safety concern about insertional mutagenesis. 
More importantly, it has been suggested that retroviral vectors can yield 
neurological improvements even though they do not cross the BBB. However, 
the retroviral vector is limited of use by their inability to transduce non-dividing 
cells, which is non-ideal for transducing brain tissue.  
 
4.4.2.2 AAV 
AAV is a single-stranded DNA (ssDNA) virus, which contains two open reading 
frames (ORFs), rep and cap, flanked by inverted terminal repeat sequences 
(ITRs). Rep is responsible for encoding proteins necessary for the viral life cycle. 
Cap encodes VP1, VP2, and VP3, which can assemble to form the viral capsid 
(102-104). To generate AAV vectors for gene therapy, the rep and cap 
sequences are replaced by an expression cassette including a promoter and the 
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gene of interest (GOI). Three plasmids (one carrying the ITRs and the GOI, one 
carrying cap and rep, and one carrying helper proteins) are co-transfected into 
cultured cells. The viral genome is packaged into capsid proteins produced within 
the transduced cells. Then, AAV virions can be purified from cell lysates with 
affinity columns, density gradients or ion exchange purification methods (105, 
106). AAV serotype 2 (AAV2) was the first serotype applied to create rAAV 
vectors (107, 108) and widely used in clinical trials worldwide. More interestingly, 
AAV9 has been shown to be able to cross the BBB and transduce neurons and 
astrocytes throughout the CNS (109-113). Therapeutic effects with AAV9-
mediated gene therapy have been demonstrated in mice (111), cats (110, 114), 
dogs (115), pigs (116) and non-human primates (117).  
 
AAV has become a powerful option as gene therapy vectors for several reasons. 
Firstly, AAV is non-pathogenic and can transduce a variety of tissues and cell 
types including brain, liver, heart, and muscle (116-119). Secondly, AAV can 
maintain stable transgene expression for up to 18 months in various animal 
models including mice, dogs, and hamsters. Thirdly, the frequency of AAV 
integrating events is very low since the viral rep gene has been removed (119, 
122). The low frequency of integration events reduces the possibility of 
insertional mutagenesis, making it more appealing than integrating vectors. 
 
However, AAV shares drawbacks of most viral vectors including the high cost of 
delivery, variable efficiencies of production and storage and immunogenicity. In 
addition, gender bias has been reported in mice and dogs treated by AAV gene 
therapy. Approximately 2 to 13 fold higher activities were measured in liver and 
serum of males compared with females after intravenous administration of AAV 
serotypes 2, 5, 8 and 9 (123-126). Another big issue in its clinical transition is 
immune response. After intravenous administration, exposure to AAV vectors 
can activate CD8+ T-cell responses against the viral capsid in a dose-dependent 
manner (127-129). Also, neutralizing antibodies to the viral capsid or the 
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expressed protein may hinder transduction of peripheral organs (130-132). Since 
AAV9 can transduce antigen-presenting cells (APCs), these vectors can also 
trigger antigen specific immune responses which lead to elimination of transgene 
expression (132).  
 
4.4.2.3 Lentivirus 
Compared to retroviral vectors, the advantage of the lentiviral vectors is that they 
can transduce non-dividing cells, rendering them suitable for transducing 
terminally differentiated cells including neurons (133). However, since 
lentiviruses integrate semi-randomly into the host genome (134), there is still 
safety concern about insertional mutagenesis.  
 
For treating MPS diseases, HIV-based lentiviral vectors have been engineered to 
deliver genes of interest into target cells achieves metabolic correction and even 
partial amelioration of neurological pathology (133-136). However, since all these 
studies cannot completely and effectively reduce neuropathology, we need 
improve the potency of lentiviral vector to treat the CNS pathology. Previous 
study in our lab has demonstrated that a single administration of lentiviral vector 
carrying IDUA gene can partially correct MPS I disease in a murine model. 
However, it was calculated that treatment of an infant would need approximately 
40 L of this lentiviral vector. Although through further concentration, it could be 
feasible to inject this amount into human patients, a more potent lentiviral vector 
should be developed. Based on codon optimization and different combinations of 
promoters and enhancers, we have designed 9 more constructs and aim to 
compare the efficacy of lentiviral gene therapy between these ten constructs. 
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Figure 1. GAG degradation and MPS diseases. The structure of heparan 
sulfate is illustrated above: repeating units of L-iduronate-2-sulfate and N-Sulfo-
D-glucosamine-6-sulphate. Iduronate sulfatase can catalyze breaking down the 
sulfate group, and its defiency leads to MPS II. After the sulfate group separating 
from the remaining part, α-L-iduronidase can break down α (1→4) linkeage 
between two components of each unit, and thus degrade heparan sulfate. 
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Chapter 2 
 
Standardization of α-L-iduronidase Enzyme Assay with Michaelis-Menten 
Kinetics 
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Abstract 
Mucopolysaccharidosis type I (MPS I) is a lysosomal disease that leads to 
progressive neurodegeneration, mental retardation and death before the age of 
10 years. MPS I results from deficiency of the lysosomal enzyme α-L-iduronidase 
(laronidase, IDUA) and subsequent accumulation of glycosaminoglycans (GAG). 
Currently, an IDUA enzyme assay with the substrate 4-methylumbelliferyl-α-L-
iduronide (4-MU iduronide) is employed to measure enzyme activity. However, 
final substrate concentrations used in the literature vary greatly, from 25 μM to 
1425 μM (Km≈180 μM). In this study, IDUA enzyme assays with 15 different 
substrate concentrations were conducted. The resulting enzyme values with 
each substrate concentration were significantly different from each other. 
Interestingly, these values obey Michaelis-Menten kinetics. Therefore, it is 
proposed that IDUA enzyme assays should be conducted (1) under substrate 
saturating conditions (>10 Km); (2) or with concentrations significantly below 
substrate saturation, and the resulting values standardized through Michaelis-
Menten kinetics.   
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1. Introduction 
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive disease, 
resulting from deficiency of α-L-iduronidase (IDUA, E.C.3.2.1.76) and subsequent 
accumulation of glycosaminoglycans (GAG). MPS I leads to systemic disease, 
including progressive neurodegeneration, mental retardation and death before 
the age of 10 years.  
 
In the efforts to treat MPS I, measurement of IDUA enzyme activity is an 
essential parameter, and is widely used in the field for research and clinical 
diagnostic testing, as well as in the regulatory evaluation of new therapies 
reviewed by US Food and Drug Administration (FDA), European Medicine 
Agency (EMEA), and other regulating bodies. Currently, an IDUA enzyme assay 
with 4-methylumbelliferyl-α-L-iduronide (4-MU iduronide) as substrate is in use. 
The assay follows the release of the 4-MU fluorophore from the substrate as a 
result of IDUA turnover. In fact, lack of methodological uniformity in the lysosomal 
enzyme activity assay was recently cited as a concern by an FDA reviewer [1].  
 
Specifically, substrate concentrations used in different labs vary greatly, from 25 
μM to 1425 μM [2-15], while the Km was found to be approximately 180 μM [16]. 
Accordingly, even the enzyme activity of the same sample within the same lab 
varies greatly (summarized in Table 1). Importantly, a kinetic reading method 
was employed in several studies [9-11]. They measured the fluorescence every 
10 min for 2 hours and stopped the reaction following a further 4-6 hours. The 
main concern arises from the most suitable pH for 4-MU fluorescence being 10.4, 
provided by the stopping buffer (glycine carbonate buffer, pH 10.4). During the 
kinetic reading, the fluorescence measured may not be accurate without a 
standardized pH. Therefore, an IDUA enzyme assay protocol with low cost, high 
accuracy and methodological standardization is desperately needed.  
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In this study, IDUA enzyme activity of liver from heterozygous mice (idua-/+) was 
measured at different substrate concentrations. The resulting values significantly 
differ from each other, but fit Michaelis-Menten kinetics well. Therefore, to obtain 
an accurate velocity (Vmax), and to make the results universally comparable, it is 
proposed that IDUA enzyme assays should be conducted either under substrate 
saturating conditions, or with concentrations significantly below substrate 
saturation, followed by standardization of the values using the Michaelis-Menten 
kinetic model. 
 
2. Material and Methods 
2.1 Collection of mouse samples 
MPS I deficient mice (idua-/-) generated by insertion into exon 6 of the 14-exon 
idua gene on the C57BL/6 background, were offsprings of breeder originally from 
Dr. Elizabeth Neufeld, UCLA. Heterozygotes (idua-/+) were genotyped by PCR. 
All mouse care and handling procedures were in compliance with the rules of the 
Institutional Animal Care and Use Committee (IACUC) of the University of 
Minnesota. Harvested organs were homogenized using a Brinkman Polytron and 
permeabilized with 0.1% Trion X-100. Tissue homogenates were diluted with 
phosphate buffered saline (PBS, 0.01 M, pH 7.4).  
 
2.2 IDUA enzyme assay 
IDUA activity was determined by a fluorometric assay using 4-methylumbelliferyl 
α-L-iduronide (4-MU iduronide, Glycosynth #44076) as the substrate. 4-MU 
iduronide was diluted with sodium formate buffer (0.4 M, pH 3.5) to different 
concentrations. Then, 25 μL aliquots of substrate of different concentrations were 
mixed with 25 μL aliquots of tissue homogenates. The mixture was incubated at 
37 °C for 30 min, and 200 μL glycine carbonate buffer (pH 10.4) was added to 
quench the reaction. IDUA catalyzed the cleavage of the non-fluorescent 
substrate (4-MU iduronide) into a fluorescent product (4-MU). 4-
Methylumbelliferone (4-MU, Sigma #M1381) was used to make the standard 
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curve. The resulting fluorescence was measured using a Bio-Tek plate reader 
with excitation at 355 nm and emission at 460 nm. IDUA enzyme activity was 
expressed in units (nmol converted to product per hour) per mg protein as 
determined with a Pierce protein assay kit (Fisher # PI22662) . All reactions were 
run in triplicate.  
 
2.3 Statistical analysis.  
For evaluation of differences between samples, post hoc Tukey test was used for 
comparisons between paired samples, and one-way analysis of variance 
(ANOVA) for comparisons between three or more samples. For evaluation of the 
Lineweaver-Burk plot, linear regression analysis was conducted. The linearity of 
this plot was determined by an adjusted R squared value and the p value. All 
data analysis was conducted with SAS 9.3 (North Carolina, USA).  
 
3. Results and discussion 
According to Michaelis-Menten kinetics [17], below substrate saturation, velocity 
increases as substrate concentration increases. To test this in the context of the 
IDUA enzyme assay, liver was harvested from heterozygous mice (idua-/+, n=3) 
and IDUA enzyme activity was measured with 15 different final substrate 
concentrations (25, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 250, 500, 2000 
and 4000 μM). Interestingly, the resulting mean activity values varied from 
0.5±0.02 to 4.1±0.37 nmol/h/mg. Significant differences were found between 
enzyme assays using different substrate concentrations. Furthermore, these 
calculated values obeyed Michaelis-Menten kinetics (Figure 2). After the 
substrate concentration increased to 2000 μM, the velocity plateaued. From the 
Michaelis-Menten plot, the Vmax is approximately 4.5 nmol/h/mg, and Km is 
approximately 174.2 μM (V= Vmax /2). This value of Km was similar to the 
numbers reported previously [16] (Km≈180 μM). 
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To confirm these values gave a linear fit on a Lineweaver-Burk plot and to obtain 
accurate Vmax and Km values [18], liver was harvested from heterozygous mice 
(idua-/+, n=7) and IDUA enzyme activity was measured for 11 different final 
substrate concentrations (40, 50, 60, 80, 100, 120, 140, 160, 180, 200 and 250 
μM ). Significant differences were again found between enzyme assays with 
different substrate concentrations (p<0.0001). A Lineweaver-Burk plot was made 
by a linear regression analysis, with a slope of 43.313 (p<0.0001), intercept of 
0.226 (p<0.0001) and adjusted R squared value of 0.9829 (Figure 3). Thereby, 
Km and Vmax were determined (Km = 191 μM, Vmax = 4.42 nmol/h/mg). This value 
of Km was similar to the numbers reported previously [16] (Km≈180 μM).   
 
Importantly, Michaelis-Menten kinetics only applies to initial velocity. Therefore, 
one underlying assumption is that substrate concentration is sufficient to remain 
almost unchanged during the reaction ([S] ≈ [S0]). Elsewhere, as substrate is 
consumed, the velocity will decrease. To determine the appropriate incubation 
time, 25 μL plasma from heterozygous mice (idua-/+) was mixed with 25 μL 
substrate (final [S] = 180 μM). All reactions were divided into 5 groups, and one 
group of reactions was quenched every 10 min. After the fifth group was 
quenched, the fluorescence was measured (Figure 4). The resulting curve was 
linear (R2=0.9953), indicating that the velocity stays stable through 50 minutes at 
the substrate concentration of 180 μM.  
 
Therefore, it is proposed to standardize the IDUA enzyme assay through two 
options. (a) IDUA enzyme assay under substrate saturating conditions to obtain 
Vmax directly. (b) IDUA enzyme assay using a final substrate concentration of Km. 
To determine Vmax in this situation, the resulting values are multiplied by 2, as the 
Michaelis-Menten equation simplifies to  when [S]=Km. 
Alternatively, other concentrations significantly below substrate saturation can be 
used and adjusted accordingly with the Michaelis-Menten equation:  . 
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Notably, when using non-saturating substrate concentrations, one must ensure 
that the velocity is relatively stable throughout the whole incubation time. 
Considering the cost of 4-MU iduronide, the latter option that utilizes lower 
substrate concentrations would be preferable.  
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IDUA 
activity 
(nmol/h/mg) 
Final 
[S] 
(μM) 
Substrate 
source 
Adjustment Incubation 
time 
(hour) 
Reaction 
temperature(℃) 
Ref. 
0.8 25 CalBiochem N 1 22 [2] 
2 25 CalBiochem N 1 22 [3] 
0.3 25 Glycosynth N 1 37 [4] 
0.6 25 Glycosynth N 1 37 [5] 
0.8 25 Glycosynth N 1 37 [6] 
2.5 25 Glycosynth N 1 37 [7] 
2.1 50 CalBiochem N 1-6 37 [8] 
0.8 50 TRC N 6-8 37 [9] 
1.6 50 TRC N 6-8 37 [10] 
6 50 CalBiochem N 6-8 37 [11] 
6.6 1000 CalBiochem N 17 37 [12] 
0.9 1425 CalBiochem N 6 37 [13] 
2.8 1425 Glycosynth N 6 37 [14] 
6 1425 Glycosynth N 6 37 [15] 
4.4 180 Glycosynth Y 0.5 37 
This 
study 
 
Table 1. Comparison of IDUA enzyme activity in liver of heterozygous 
mice from different studies. Enzyme levels were divided by 2 if only values in 
wild type mice were provided in the original paper (IDUA enzyme activities in 
heterozygous mice are approximately half of that in wild-type individuals). N=NO, 
Y=YES. 
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Figure 2. Michaelis-Menten analysis of IDUA enzyme activity in liver 
from normal heterozygous mice (idua-/+). Each dot is the average value from 
3 mice. The line indicates the approximate plateau that defines Vmax. This figure 
is produced by fitting a hyperbolic curve through TriLookup software. 
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Figure 3. Lineweaver-Burk analysis of IDUA enzyme activity in liver from 
normal heterozygous mice (idua-/+). Each dot is the average value from 7 
mice. 
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Figure 4. IDUA enzyme assay with a final substrate concentration of 180 μM 
is linear through 50 min. Five groups of reactions were quenched at different 
time-points (10, 20, 30, 40, and 50 min), and the fluorescence was measured. 
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Chapter 3 
 
High-Dose Enzyme Replacement Therapy in Murine Hurler Syndrome 
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Abstract 
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive disease which 
leads to systemic disease, including progressive neurodegeneration, mental 
retardation and death before the age of 10 years. MPS I results from deficiency 
of α-L-iduronidase (laronidase, IDUA) in lysosomes and subsequent 
accumulation of glycosaminoglycans (GAG). Clinical enzyme replacement 
therapy (ERT) with intravenous laronidase reverses some aspects of MPS I 
disease (e.g., hepatomegaly, splenomegaly, glycosaminoglycanuria) and 
ameliorates others (e.g., pulmonary function, cardiac disease, arthropathy, 
exercise tolerance). However, neurologic benefits are thought to be negligible 
because the blood-brain barrier (BBB) blocks enzyme from reaching the central 
nervous system (CNS). We considered the possibility that a very high dose of 
intravenous laronidase might be able to transit across the BBB in small 
quantities, and provide some metabolic correction in the brain. To address this 
question, we administered high-dose laronidase (11.6 mg/kg, once per week, 4 
weeks) to adult MPS I mice. IDUA enzyme activity in cortex of injected mice 
increased to 97% of that in wild type mice (p<0.01). GAG levels in cortex were 
reduced by 63% of that from untreated MPS I mice (p<0.05). Further, 
immunohistochemical analysis showed that the treatment reduced secondary 
storage material GM3-ganglioside in treated MPS I mice. Water T-maze tests 
showed that the learning abnormality in MPS I mice was surprisingly reduced 
(p<0.0001). In summary, these results indicated that repeated, high-dose ERT 
facilitated IDUA transit across the BBB, reduced GAG accumulation within the 
CNS, and rescued cognitive impairment. 
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1. Introduction 
MPS I is an autosomal recessive inherited disease that leads to systemic, 
progressive neurodegeneration, mental retardation and death before the age of 
10 years. Hurler syndrome (MPS IH, OMIM #67014) results from deficiency of α-
L-iduronidase (IDUA, E.C.3.2.1.76), which degrades the GAG heparan sulfate 
and dermatan sulfate. The widespread accumulation of GAG leads to 
progressive cellular damage and organ dysfunction, with the central nervous 
system (CNS) being one of the primary sites of pathology. The CNS pathology in 
Hurler syndrome patients is severe, manifested by hydrocephalus, mental 
retardation, learning delays and dementia.  
 
Clinical IDUA ERT ameliorates exclusively certain visceral defects [1]. The 
uptake of infused laronidase to affected tissues relies on the mannose 6-
phosphate receptor (M6PR), which is down-regulated in the blood-brain barrier 
after the first two weeks of life [2]. Further, infused IDUA is rapidly cleared from 
the circulation by M6PR and mannose receptor (MR) [3]. As a result, neurological 
benefits of ERT with the conventional dose are thought to be negligible because 
the BBB blocks infused enzyme from reaching the CNS [4, 5]. Novel therapies 
leading to metabolic correction in the CNS and neurological benefits are 
desperately needed. 
 
High-dose ERT has been shown in several lysosomal disease animal models to 
ameliorate neuropathology, including mice with aspartylglycosaminuria [6], 
Krabbe disease [7], MPS VII [8], α-mannosidosis [9,10], arylsulfatase A 
deficiency [11,12], MPS II [13], and guinea pigs with α-mannosidosis [14]. 
However, a high-dose ERT study [15] conducted in MPS IIIA mice showed no 
neurological benefits, indicating a potential difference in mechanisms of enzyme 
uptake or that the dose required in MPS IIIA is higher than other lysosomal 
diseases. 
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In this study, a single or multiple injections of high-dose IDUA was administered 
in an MPS I mouse model. For the first time, this study showed that repeated, 
high-dose ERT allows sufficient enzyme delivery to the CNS and improves 
cognitive function. These results may lead to improved treatment for MPS I 
patients with cognitive impairment. 
 
2. Material and Methods 
2.1 MPS I mice and injection 
MPS I deficient mice (idua-/-), a kind gift from Dr. Elizabeth Neufeld, UCLA, were 
generated by insertion of neomycin resistance gene into exon 6 of the 14-exon 
IDUA gene on the C57BL/6 background. MPS I mice (idua-/-) and heterozygotes 
(idua-/+) were genotyped by PCR. Aldurazyme® (BioMarin Pharmaceutics) was 
concentrated by centrifugation in Amicon Ultra Centrifugal Filters (Millipore) to a 
final concentration of ~1.2 mg/mL or 11.6 mg/mL. The preparations were diluted 
in 120 μL phosphate buffered saline (PBS), and injected over 10-15 seconds by 
the tail vein at the dose regimens detailed in the Results section.  All mouse care 
and handling procedures were in compliance with the rules of the Institutional 
Animal Care and Use Committee (IACUC) of the University of Minnesota. 
 
2.2 IDUA enzyme assay 
IDUA activity was determined by a fluorometric assay using 4-methylumbelliferyl 
α-L-iduronide (4-MU iduronide, Glycosynth #44076) as the substrate. 4-MU 
iduronide was diluted with sodium formate buffer (0.4 M, pH 3.5) to different 
concentrations. Then, 25 μL aliquots of substrate of different concentrations were 
mixed with 25 μL aliquots of tissue homogenates. The mixture was incubated at 
37 °C for 30 min, and 200 μL glycine carbonate buffer (pH 10.4) was added to 
quench the reaction. IDUA catalyzed the cleavage of the non-fluorescent 
substrate (4-MU iduronide) into a fluorescent product (4-MU). 4-
Methylumbelliferone (4-MU, Sigma #M1381) was used to make the standard 
curve. The resulting fluorescence was measured using a Bio-Tek plate reader 
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with excitation at 355 nm and emission at 460 nm. IDUA enzyme activity was 
expressed in units (nmol converted to product per hour) per mg protein as 
determined with a Pierce protein assay kit (Fisher # PI22662) . All reactions were 
run in triplicate. 
 
2.3 Tissue GAG assay 
Tissue GAG assays were conducted as described previously [16]. The 
supernatants of tissue homogenates were treated by Proteinase K (NEB 
#CX27439) with the ratio of 3(Pro K):1(sample), incubated at 55°C for 24 hours, 
and boiled for 10 min to inactivate the enzyme. Then, samples were incubated 
with 250 U DNase (Sigma # D4527-10KU) and 2.5 μg RNase (Sigma # R6513-
10MG) at room temperature for 24 hours. After boiling for 10 min to inactivate the 
enzymes, GAG concentration was determined by the Blyscan Sulfated 
Glycosaminoglycan Assay (Biocolor Inc). Results were expressed as μg GAG/mg 
protein. 
 
2.4 Water T-maze test 
Water T-maze test was conducted as described previously [17]. Four days after 
the third injection, mice from all three groups were subjected to water T-maze 
testing which assessed the learning ability of mice. A pool was filled 
approximately 10 cm deep with water (room temperature) mixed with non-toxic 
white acrylic paint in order to prevent visual detection of submerged objects. A 
"T" shape maze was set in the water, and a platform, at the end of the left (or 
right) arm, was submerged 0.5-1 cm below the surface of the water. In run #1, a 
barrier was placed across one arm. Mice were released at the base of the "T", 
forced to swim to the top, and choose either the left or right arm to locate the 
platform. Then, in run #2, the barrier was removed and the platform was placed 
at the end of the other arm. The correct choice was the alternate arm from where 
the platform was placed in run #1. Each mouse performed 8 trials per day for 8 
days.  
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2.5 Immunofluorescence 
Immunofluorescence was conducted as described previously [18]. Mice were 
perfused with 20 mL 0.01 M PBS and sacrificed. The brain was removed, fixed 
overnight in paraformaldehyde and cryopreserved in 30% sucrose. Then, the 
brain was frozen on dry ice and sectioned coronally. After washing, free-floating 
sections were blocked with PBS containing 5% normal goat serum and 0.3% 
Triton X-100. Primary antibody against GM3-ganglioside (1:50, Abcam) was 
added and the sections were incubated at 4°C overnight. After washing, sections 
were incubated with goat-anti mouse IgM (Antibodies-online) and DAPI (Sigma) 
at room temperature for 1 hour. After mounting on the slides, sections were 
examined with a microscope (Zeiss). 
 
2.6 Enzyme-linked immunosorbent assay (ELISA) 
ELISA was conducted as described previously [19]. Aldurazyme (BioMarin 
Pharmaceutics) was diluted with Tris-buffered saline (pH=7.4) to a final 
concentration of 4 μg/mL. In a 96-well microplate, 50 μL diluted Aldurazyme was 
incubated at 4°C overnight. After washing and blocking with Tris-buffered saline 
containing 1% BSA at room temperature for 2 hours, 100 μL serum (1:50 
dilutions) was incubated at room temperature for 1 hour. After washing, the wells 
were incubated with 100 μL anti-mouse IgG alkaline phosphatase conjugate 
(Abcam #97027) at room temperature for 1 hour. After washing, the wells were 
incubated with 200 μL of 1 mg/ml p-nitrophenyl phosphate chromogenic 
substrate (Sigma # P7998-100ML) at room temperature for 1h. Then, 50 μL 
EDTA (0.1 M, pH 8.0) was added to stop the reaction. Absorbance at 405 nm 
was quantified by using a Bio-tek plate reader. 
 
2.7 Statistical analysis 
Data are represented as mean±standard error. For evaluation of differences 
between samples, Tukey test for comparisons between paired samples and one-
   37 
 
way or two-way analysis of variance (ANOVA) for comparisons between three or 
more samples were applied. Statistical significant level was set at p<0.05. Data 
analysis was conducted with SAS 9.3.  
 
3. Results 
3.1 Biodistribution of IDUA after single high-dose ERT  
An initial experiment was designed to determine the potential effects of high-dose 
ERT on the transit of laronidase across the BBB. A single injection of 0.58 mg/kg 
(0.7×104 pmol/kg, clinical standard dose) or ~1.2 mg/kg (1.4×104 pmol/kg, 
approximately 2 fold the standard dose) laronidase (Aldurazyme) was 
intravenously administered to adult MPS I mice (idua-/-, 10 to 20 weeks old, n=6 
for high-dose group, n=7 for normal-dose group) by the tail vein. Age-matched 
untreated MPS I mice (n=7) and heterozygotes (idua-/+, n=6) were included as 
controls. It has been shown that the plasma half-life of infused IDUA in dogs is 
approximately 20 min [20]. Although there might be a difference in plasma half-
life between dogs and mice, we presumed that 2 hours would be sufficient for 
infused IDUA to enter the tissues. Two hours after the injection, all mice were 
sacrificed, and multiple organs including brain cortex, cerebellum, heart, liver, 
lung and spleen were collected. IDUA enzyme activity in tissue homogenates 
was assessed by IDUA enzyme assay. In liver and spleen, which acquired the 
highest enzyme concentration, the IDUA enzyme activity in the high-dose group 
increased to 98-fold and 24-fold of that in wild-type mice, respectively (Figure 5). 
In lung and heart, the IDUA enzyme activity in the high-dose group increased to 
24-fold and 93% of that in wild-type activity, respectively. Moreover, IDUA 
enzyme activity in brain cortex of the high-dose group mice increased to 10.1% 
of that in wild-type mice. There was no significant increase in enzyme activity in 
cerebellum. In the normal-dose group, we also observed enzyme activity 
increases in heart, liver, lung and spleen. However, compared with untreated 
MPS I mice, no significant increase was observed in brain cortex or cerebellum 
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of the normal-dose group. Also, no statistically significant age or gender effects 
were found in IDUA enzyme activity. 
 
Serum was collected prior to sacrifice, and high IDUA enzyme activity was 
observed in treated MPS I mice: 110.6±49.8 nmol/h/mg for high dose group and 
78.4±25.3 nmol/h/mg for normal dose group. IDUA enzyme activity in 
heterozygous and untreated MPS I mice was almost non-detectable. Although 
perfusion was conducted, there is still a possibility that the enzyme activity 
increase in brain cortex can be attributed to serum within brain capillaries.  
 
3.2 Biodistribution of IDUA after repeated, high-dose ERT 
Based on the results of aforementioned single high-dose ERT and high-dose 
ERT studies on other lysosomal disease models, we designed a repeated ERT 
schedule with a 20-fold higher than the human therapeutic dose (~11.6 mg/kg 
body weight, 1.4×105 pmol/kg). Adult MPS I mice (11.7±2.7 week old, n=12) 
received 4 injections of 20-fold dose IDUA once a week. Age-matched untreated 
MPS I mice (idua-/-, n=11) and heterozygotes (idua-/+, n=11) were included as 
controls. All mice were sacrificed five days after the 4th injection, and multiple 
organs were collected.  
 
An increase in enzyme activity was observed in heart (1.9-fold of wild-type 
activity), liver (95.1-fold of wild-type activity), lung (3.4-fold of wild-type activity) 
and spleen (21.5-fold of wild-type activity) (Figure 6A, B). IDUA enzyme activity 
in brain cortex and cerebellum of treated MPS I mice increased to 97% and 1.2-
fold of that in wild-type mice, respectively (Figure 6A). Also, no statistically 
significant age or gender effects were found in IDUA enzyme activity. Serum was 
collected on D3, D10 and D26 (injection on D0, D7, D14, D21). Since IDUA 
enzyme levels in serum of treated mice were undetectable (data not shown), the 
enzyme activity increase in cortex and cerebellum cannot be simply explained by 
the presence of blood in the capillaries of the brain.  
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3.3 Reduced tissue GAG accumulation after repeated, high-dose ERT 
To determine the effect of repeated, high-dose ERT on GAG accumulation, GAG 
was quantified in tissue homogenates. Liver and spleen acquired the highest 
enzyme levels after injection, correspondingly, GAG accumulation was reduced 
the most in these two organs: by 92%, and 83%, respectively (Figure 7B). Also, 
GAG accumulation in heart and lung was reduced by 76% and 87%, respectively 
(Figure 7A, B). GAG accumulation in cortex was reduced by 63% (Figure 7A). 
Also, no statistically significant age or gender effects were found in GAG 
accumulation. 
 
To further validate the GAG accumulation reduction within the CNS, 
histochemical analysis was conducted. Secondary accumulation of GM3-
ganglioside was apparent in the brains of untreated MPS I mice, visualized by 
positive immunofluorescence staining of punctate aggregates throughout most of 
the brain (including thalamus, hippocampus and nuclei septi). In contrast, only a 
few punctate aggregates were observed in the same regions of brains from 
treated MPS I mice (Figure 8).  
 
3.4 Cognitive improvements after repeated, high-dose ERT 
Water T-maze tests were employed to evaluate learning behavior.  Five days 
after the third injection, mice from all three groups were subjected to 8 trials of 
water T-maze tests per day for a duration of 8 days. For each mouse, the 
percentage of finding the platform correctly was recorded. On D0, mice from all 
three groups had a similar correct percentage (36 to 42%). However, the 
heterozygote (idua-/+) group improved significantly over the testing period, 
reaching a final level of 75%. Treated MPS I mice also improved significantly 
during the trials, reaching a final level of 67%. In contrast, untreated MPS I mice 
only improved modestly from 36% to 45%. Since this test is mainly about 
decision-making, swimming speed was not recorded nor evaluated. Also, the 
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platform was underneath opaque water, eye disease of MPS I mice is unlikely to 
be a confounding factor. There did not appear to be any physical defects in the 
MPS I mice that could have affected the results. Water T maze tests showed that 
learning abnormalities observed in MPS I mice were reduced significantly by 
repeated, high-dose ERT (Figure 9, p<0.0001).These results showed that by 
repeated, high-dose ERT, the CNS pathology in MPS I mice was functionally 
rescued. 
 
3.5 Anti-IDUA immune response after repeated, high-dose ERT 
Several previous studies showed that infused IDUA elicited humoral immune 
response in patients and animal models [19, 21]. Serum was collected from 12 
mice of the three groups at different time-points and processed for ELISA. In 
treated MPS I mice, a significant increase in anti-IDUA antibody concentration 
was observed after the second injection (Figure 10A). Also, right before sacrifice, 
serum was collected from 29 mice of the three groups and processed for ELISA. 
In treated MPS I mice, there were significant higher antibody levels compared 
with the other two groups (Figure 10B).  
 
Strong adverse infusion reactions were found in some treated mice after the 
second injection but were alleviated by injection of 2 mg/kg dexamethasone 1 
hour prior to enzyme infusion, prior to the subsequent injections. Based on 
ELISA data, treated mice can be divided into two groups: those with or without 
high anti-IDUA levels. However, no significant difference in enzyme activity, GAG 
accumulation or performance in behavior tests was observed between these two 
groups. 
 
4. Discussion 
4.1 Limitations of ERT 
Progressive neurodegeneration in MPS I patients is a devastating feature leading 
to dramatic intellectual impairment. ERT has already been used in clinical 
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application for treating MPS I and other lysosomal diseases. Delivery of infused 
enzymes to lysosomes is mediated by MR on macrophages or ubiquitously 
expressed M6PR. A previous study in mice has shown that M6PR-mediated 
transcytosis in the BBB is down-regulated after two weeks of life [2]. As a result, 
although ERT can achieve significant visceral storage reduction, neurological 
improvements are thought to be negligible. It has been a long-held dogma that 
the BBB prevents the transit of lysosomal enzymes from the blood to the 
interstitial space surrounding neuronal and glial cells of the CNS. Any means of 
delivering enzyme across the BBB would be of major clinical significance.  
    
In this study of high-dose ERT, the most corrective effect was achieved in liver 
and spleen, which took up the majority of infused IDUA, as shown by IDUA 
enzyme assays. The IDUA enzyme activity in brain cortex reached 50% of that in 
wild-type mice. Considering the fact that only a small amount of IDUA can make 
a great difference in patients, this significant increase in the CNS has promise of 
providing therapeutic benefits [22-24]. Consistent with this observation, total 
GAG accumulation in brain cortex was reduced after 4 injections. Further, 
behavior analysis showed that even when the CNS impairment is clearly 
manifested, high-dose ERT can be effective in preventing and possibly correcting 
this impairment. 
 
4.2 Analysis of Mechanism 
Less than 200 μL of laronidase was administered by the tail vein, ruling out the 
possibility of passage of enzyme through the blood-brain barrier as the result of a 
hydro-dynamic effect resulting from the rapid injection of a large volume of 
enzyme solution. Also, blood from each mouse was collected right before 
sacrifice, and plasma IDUA enzyme levels in treated mice were approximately 0 
(data not shown). This result excludes the possibility of blood contamination of 
the brain. Furthermore, although we could not directly visualize IDUA in brain 
sections with antibody staining (data not shown), increased enzyme activity, 
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decreased GAG concentrations and decreased GM3-ganglioside suggest that 
infused IDUA reached the CNS tissue.                                                                                                                                                                                                              
    
The mechanism by which intravenous IDUA transits across the BBB and reaches 
the brain remains an open question at present. One possibility may be fluid-
phase pinocytosis. This type of uptake is strictly dependent on concentrations 
and is relatively slow. High-dose ERT can lead to a high enzyme level in blood, 
which makes it possible for fluid-phase pinocytosis to be effective. Another 
possibility is the extracellular pathway which has been shown to allow small 
amounts of molecules as large as albumin to cross the BBB [25]. Also, there 
exists the possibility that residual M6PR or other uncharacterized receptors more 
efficiently facilitate the transit of IDUA in the context of high plasma enzyme 
levels. However, we cannot rule out the possibility that the integrity of the BBB in 
MPS I mice might be impaired by disease-related factors. Identifying the 
mechanism of delivery of IDUA to brain may suggest strategies to enhance the 
process and make ERT for CNS disease reduction a more realistic goal.  
 
4.3 Implications and Future Directions 
The inability of normal-dose ERT to correct pathology within the CNS may be 
due to two obstacles: 1) other tissues, e.g. liver and spleen, internalizing most of 
the infused IDUA, preventing sufficient enzyme delivery to the CNS; 2) antibody 
binds the infused IDUA, further reducing the efficiency of delivery to the CNS. 
Several high-dose ERT studies have been conducted in other lysosomal disease 
animal models. Most studies showed a surprising enzyme delivery to the CNS 
(results summarized in Table 2), indicating that the BBB is not impermeable to 
infused enzymes. Therefore, it is a matter of 'inefficiency' rather than an 
insurmountable obstacle. The inefficiency of the CNS delivery in normal-dose 
ERT may be circumvented by high-dose ERT. 
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High humoral immune response against IDUA was identified in treated mice by 
ELISA. In spite of high anti-IDUA antibody levels, significant increase in IDUA 
enzyme activity was observed and GAG accumulation was reduced. In fact, a 
recent study showed that development of antibodies to IDUA negatively 
correlates with improvement in performance on behavioral tests in murine MPS 1 
[26]. It will be interesting to see whether infused IDUA can efficiently cross the 
BBB in immunotolerant or immunodeficient animals. In addition, minimizing the 
immune response perhaps by modifying the epitopes of IDUA enzyme can be a 
promising future direction.  
 
4.4 Significance 
A recent murine study, using 1.2 mg/kg dose every 2 weeks (equivalent to 
clinical standard dose 0.58 mg/kg per week) achieved GAG reduction in brain 
and neurological improvements [26]. Similarly, a canine study showed that dogs 
treated from birth with ERT (0.58 to 1.57 mg/kg) also led to reduction of GAG 
accumulation in the brain [27]. This study, for the first time, assessed repeated 
high-dose ERT in MPS I mice. Using a 20-fold dose (11.6 mg/kg) compared to 
the generally accepted therapeutic dose in people, may not be applicable to 
patients considering the cost and immune response. However, it has been 
suggested that dose conversion using body surface area (BSA) instead of body 
weight is more appropriate [28]. According to a formula provided by the Food and 
Drug Administration [29], 11.6 mg/kg in this murine study would be approximately 
0.94 mg/kg in adult patients, which is not a great increase from the standard 
dose (0.58 mg/kg). These facts make this study more meaningful in terms of 
potential clinical application: only a small increase in dose may make a great 
difference. These results provide the proof of principle: when the enzyme level is 
high enough, a small amount of IDUA can cross the BBB of adult animals, and 
provide neurological benefits. Although intraventricular [18], and intrathecal [31, 
32] administration of enzyme or gene vector have produced neurological 
improvements, these strategies are limited by their invasive nature. The best 
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therapeutic strategy might be the one that delivers enzyme uniformly to the brain. 
Considering the fact that each neuron is estimated to be approximately 15 μm 
from blood vessels, the bloodstream would be an ideal conduit for enzyme 
delivery. 
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Animal 
model 
Immuno- 
compete
nt 
 Doses(n) 
Enzyme 
activity 
achieved  
(% 
Normal) 
Brain 
storage 
reduced 
(%Affect
ed)  
Reduced 
Neuropatholo
gy 
       
Referenc
e  
α-
mannosidosi
s mice 
   Y  
250 
U/kg(2) 
  ND             74%       ND     [9]  
α-
mannosidosi
s mice 
   Y  
500 U/kg 
(2) 
  15%    50%       Y     [10]  
α-
mannosidosi
s  pigs 
   Y  
10 mg/kg 
(1) 
  ND                ND               Y     [14]  
ASA mice     Y  
20 mg/kg 
(4) 
  ND          30%       Y     [11]  
ASA mice     N  
50 mg/kg 
(52) 
  ND    34%        Y     [12]  
AGU mice    Y  
10 mg/kg 
(8) 
  10%    20%        Y     [6]  
Krabbe mice    Y  6 mg/kg   7%    18%        Y     [7]  
MPS II mice    Y  
10 mg/kg 
(45) 
  5%    ND       Y     [13]  
MPS IIIA 
mice 
   Y  
20 mg/kg 
(4) 
  22%    0        N     [15]  
MPS VII 
mice 
   N  
20 mg/kg 
(4) 
  2.5%     ND       Y     [8]  
MPS I mice    Y  
11.6 mg/kg 
(4) 
  97%     63%        Y  
  This 
study 
Table 2. Summary of outcomes from high-dose ERT studies conducted on 
animal models of lysosomal diseases with neurodegeneration. Y= yes; 
N=no; ND = not determined. 
   46 
 
 
 
Figure 5. IDUA enzyme activity in multiple organs increased after a single 
injection of ~1.2 mg/kg laronidase.  A total of 28 age-matched mice were 
assigned into four groups: 1) MPS I mice (idua-/-, n=6, white columns) injected 
with 2 fold (~1.2 mg/kg) laronidase; 2) MPS I mice (n=6, dark columns) injected 
with normal-dose (0.58 mg/kg) laronidase; 3) MPS I mice (n=6, hatched columns) 
with no injections; 4) heterozygote (idua+/-, n=5, diamond columns) with no 
injections. Data are mean ± standard errors. * p<0.05. 
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Figure 6. IDUA enzyme activity in multiple organs increased after 4 
injections of ~11.6 mg/kg laronidase.  A total of 34 age-matched adult mice 
were assigned into four groups: 1) MPS I mice (idua-/-, n=12, white columns) 
injected with 20 fold (~11.6 mg/kg) laronidase; 2) MPS I mice (n=11, hatched 
columns) with no injections; 3) heterozygote (idua+/-, n=11, dark columns) with 
no injections. Data are mean ± standard errors. * p<0.05. 
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Figure 7. GAG accumulation reduced in multiple organs after 4 injections of 
~11.6 mg/kg laronidase. Data are mean ± standard errors, p values are 
calculated by one-way ANOVA and Tukey test. * p<0.05. Treated MPS I: white 
columns; untreated MPS I: hatched columns; heterozygous mice: dark columns. 
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Figure 8. Secondary storage material GM3-ganglioside was reduced in the 
hippocampus region of treated MPS I mice. (Red: GM3; Blue: DAPI. Left: 
untreated MPS I; right: treated MPS I) 
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Figure 9. Learning abnormality in MPS I mice was surprisingly reduced by 
repeated high-dose ERT. Five days after the third injection, all three groups 
underwent 8-day water T maze test which investigate learning ability of mice. X 
axis values mean time in days. Data are mean ± standard errors, p value was 
calculated by two-way ANOVA. 
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Figure 10. Anti-IDUA immune response detected after repeated high-dose 
ERT. (A) The IDUA antibody levels were measured by ELISA in serum collected 
at various time-points (D3, D10, D26). X axis values mean time in days. The 
serum was tested at 1:50 dilution. (B) Serum from a total of 29 mice were 
collected right before sacrifice. The IDUA antibody levels were measured by 
ELISA. The serum was tested at 1:50 dilution. Data are mean ± standard errors. 
* p<0.05. 
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Chapter 4 
 
Lentiviral Gene Therapy for Hurler Syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   53 
 
 
Abstract 
Mucopolysaccharidosis type I (MPS I) is a lysosomal disease caused by α-L-
iduronidase (IDUA) deficiency and subsequent accumulation of 
glycosaminoglycan (GAG) heparan sulfate and dermatan sulfate. Lentiviral 
vector encoding correct IDUA sequence could be used for gene therapy treating 
MPS I disease. Previous study in our lab showed that intravenous injection of a 
lentiviral vector (CSP1) into neonatal MPS I mice achieved metabolic correction 
and neurological improvements. To improve the efficacy of this lentiviral gene 
therapy, 9 more lentiviral constructs were designed by codon optimization, 
different combinations of promoters and enhancers. These ten plasmids were 
transfected into HEK 293FT cells, and IDUA enzyme activity in cell lysates and 
supernatants were compared. The transfection efficiencies of each plasmid were 
comparable (~60%), shown by co-transfection of a plasmid encoding GFP. A 
total of 5 plasmids showed higher enzyme activity in cells (from 6,482 ± 1,258 to 
7,358 ± 956 nmol/h/mg) than CSP1 (5,613 ± 1,047 nmol/h/mg). These 5 
candidates also had the highest enzyme activity in supernatants (514 ± 213 
nmol/h/mL to 861 ± 151 nmol/h/mL). Therefore, these 5 plasmids and CSP1 
were selected for lentiviral vector production and further in vivo comparison. A 
total of 6 lentiviral vectors will be injected into temporary facial vein in neonatal 
MPS I mice, and tissue IDUA levels on day 30 will be compared to select the 
optimal vector, which has the highest IDUA levels. These results will pave a way 
for developing a directly applicable lentiviral gene therapy clinical trial for MPS I 
patients, and provide proof-of-concept evidence for treating other lysosomal 
diseases. 
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1. Introduction 
The CNS pathology in human Hurler syndrome patients is severe, manifested by 
hydrocephalus, mental retardation, learning abnormality, dementia and even 
death before the age of 10 years. Brain, bone, and heart valves are difficult-to-
reach sites for enzyme due to the inefficient enzyme diffusion. Specifically, the 
CNS pathology of Hurler syndrome is extremely difficult to treat because the BBB 
blocks the entry of enzyme into the CNS (1, 2). HSCT can only achieve partial 
neurological improvements, which is manifested by low IQ and neurocognitive 
disability in patients (3). While ERT is thought to have negligible neurological 
improvements, it has been shown that a high dose infusion of IDUA can lead to 
significant increase of enzyme activity in the brain cortex (4). Considering the fact 
that a small amount of enzyme is sufficient to improve neurological pathology (5-
7), this should be sufficient to treat neurological pathology. However, ERT is 
limited by the need for frequent, life-long, expensive treatments. Moreover, high 
dose treatment is not plausible for clinical application considering the immune 
response against infused enzyme (8).  
 
Gene therapy has emerged as a promising strategy for treating MPS I diseases. 
In the past few years, gene therapy for MPS I disease with different vectors in 
animal models has been conducted, which include retrovirus (9, 10), lentivirus (8, 
11), adeno-associated virus (AAV) (3, 12-14), Sleeping Beauty (SB) transposon 
(15) and minicircles (16).  
 
Lentiviral vector can transfer genes into a variety of non-dividing cell types, 
including neurons, retinal cells, muscle cells and hematopoietic stem cells 
(HSCs). Neurological improvements have been shown in disease animal models 
after injection of lentiviral vector directly into the brain (17). Previous study in our 
lab has showed that a single intravenous administration of lentiviral vector (CSP1) 
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into neonatal MPS I mice can achieve metabolic correction and neurological 
improvements. These results demonstrated the efficacy of neonatal lentiviral 
vector administration for treating Hurler syndrome, with implications for treatment 
of other lysosomal diseases. However, it is difficult to apply the dose used in this 
study into clinical trials. In light of this, we designed 9 more constructs by codon 
optimization, different combinations of promoters and enhancers, which are 
expected to have better transgene expression. In this study, we compared the 
transgene expression of these 10 plasmids in cultured cells and identified 5 
candidates which have the highest transgene expression. These 5 candidates, 
together with CSP1, have been produced into lentiviral vectors and will be tested 
in neonatal MPS I mice through intravenous administration. 
 
2. Methods 
2.1 Plasmid construction 
The human IDUA cDNA generated by reverse transcription PCR (RT-PCR) 
amplification from total mRNA of an unaffected individual was inserted into the 
multi-cloning sites of pHIV-CS. The IDUA expression was under the control of 
PGK promoter and named as pSCP1. Then, codon optimization of IDUA cDNA 
sequence was performed, resulting in oIDUA sequence. By adding different 
promoters (CLP, PGK and EF-1α) and variants of WPRE, we constructed 9 more 
plasmids as followed: pCEFID, pCEFoID, pCPGKoID, pCCLPoID, pCEFoID-M1, 
pCEFoID-M2, pCEFoID-dWPRE, pCCLPID-dWPRE and pCCLPID. All plasmids 
were confirmed by sequencing. The plasmid construction was done previously in 
Gene Therapy and Diagnostics Laboratory (C.B. Whitley, personal 
communication). 
 
2.2 In vitro plasmid transfection 
For each transfection, 25 μg of candidate plasmid and 25 μg of HIV CMVeGFP 
plasmid were mixed with 133 μL 2.5 M CaCl2 (25˚C) and 1.33 mL RNase/DNase 
free sterile H2O. After adding 1.33 mL of 2x HEPES buffered saline (HBS, pH 
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7.1), 7 mL serum free medium was added to the mixture. Then, the HEK 293FT 
cells were incubated with this transfection solution for 4 to 6 hours (37˚C, 5% 
CO2). After removing the transfection solution, cells were incubated with 9 mL of 
10% fetal bovine serum (FBS), Dulbecco's modified eagle medium (DMEM) for 
another 48 hours. Finally, cells and medium were collected by centrifuge and 
processed for IDUA enzyme assays. The plasmid transfection was conducted by 
Iowa Viral Vector Core Facility (500 Newton Road 221 Eckstein Medical 
Research Building Iowa City, IA 52242). 
 
2.3 IDUA enzyme assay  
IDUA enzyme assay was conducted as previously described (3, 18). IDUA 
activity was determined by a fluorometric assay using 4-methylumbelliferyl α-L-
iduronide (4-MU iduronide, Glycosynth #44076) as the substrate. 4-MU iduronide 
was diluted with sodium formate buffer (0.4 M, pH 3.5). Then, 25 μL aliquots (360 
μM) of substrate were mixed with 25 μL aliquots of tissue homogenates (diluted 
with 0.2% bovine serum albumin in phosphate buffered saline). The mixture was 
incubated at 37 °C for 30 min, and 200 μL glycine carbonate buffer (pH 10.4) was 
added to quench the reaction. IDUA catalyzed the cleavage of the non-
fluorescent substrate (4-MU iduronide) into a fluorescent product (4-MU). 4-
Methylumbelliferone (4-MU, Sigma # M1381) was used to draw the standard 
curve. The resulting fluorescence was measured with a Bio-Tek plate reader with 
excitation at 355 nm and emission at 460 nm. IDUA enzyme activity was 
expressed in units (nmol converted to product per hour) per mg protein as 
determined with a Pierce protein assay kit (Fisher # PI22662) or per mL plasma. 
Then, IDUA eznyme activity was adjusted by Michaelis-Menten equation as 
described previously (18). All reactions were performed in triplicate. 
 
2.4 Statistical analysis 
Data were represented as mean ± standard errors. For evaluation of differences 
between samples, Tukey test for comparisons between paired samples and one-
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way or two-way analysis of variance (ANOVA) for comparisons between three or 
more samples were performed. Statistical significant level was set at p<0.05. 
Data analysis was conducted with SAS 9.3.  
 
3. Results 
3.1 Construct design for achieving higher transgene expression 
The original construct (CSP1) we tested in MPS I mice used the PGK promoter 
to drive expression of IDUA. The sequence information of 9 more constructs is 
shown in Figure 11. Through codon optimization, optimized IDUA (oIDUA) 
sequence was obtained and used in 6 constructs. Also, CLP and EF-1α 
promoters were selected and engineered into 3 and 5 constructs, respectively. 
Further, Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory 
Element (WPRE) was introduced into 7 constructs. WPRE contains three 
subelements: alpha, beta and gamma. Subelement gamma and alpha contribute 
to most of the enhancing function, while beta contains WHV X protein. Due to 
safety concern about the oncogenic ability of WHV X sequence, CEFoID-M1 is 
designed by creating mutations in WHV X sequence, and CEFoID-M2 is 
designed by deleting alpha and beta subelements.  
  
3.2 Comparison of plasmid transgene expression in cultured cells 
The ten plasmids were co-transfected with plasmid encoding GFP into HEK 
293FT cells. Cell lysates and supernatants were collected for IDUA enzyme 
assays (Figure 12, 13). There are 5 constructs (CEFoID, CEFoID-M1, CEFoID-
M2, CEFoID-dWPRE and CCLPoID) yielding higher IDUA levels in cells than 
CSP1. Also, these 5 constructs had the highest IDUA levels in supernatants, 
which confirmed the results within cells. CEFoID yielded higher IDUA levels than 
CEFID (7,359 ± 956 vs 4,879 ± 947 nmol/h/mg, p=0.045), while CCLPoID 
achieved higher IDUA levels than CCLPID (7,334 ± 858 vs 3,784 ± 656 
nmol/h/mg, p=0.03). These results show that codon optimization can achieve 
higher transgene expression. CEFoID and CCLPoID had IDUA levels at 7,359 ± 
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956 and 7,334 ± 858nmol/h/mg, respectively, which is higher than that of 
CPGKoID (3,732 ± 106 nmol/h/mg, p<0.02). These results show that EF-1α and 
CLP promoter can achieve higher transgene expression. Also, we compared 
constructs with or without WPRE (CEFoID vs CEFoID-M1 vs CEFoID-M2 vs 
CEFoID-dWPRE), although CEFoID-dWPRE had lower IDUA levels than the 
other three constructs, it is not statistically significant. This observation was 
confirmed when comparing CCLPID (3,784 ± 656 nmol/h/mg) and CCLPID-
dWPRE (3,221 ± 302 nmol/h/mg). Collectively, through in vitro transfection 
studies, we identified 5 candidates (CEFoID, CEFoID-M1, CEFoID-M2, CEFoID-
dWPRE and CCLPoID) for packaging into lentiviral vectors. 
 
5. Discussion 
Previous studies have showed that the effects of gene therapy ultimately depend 
on an interplay of the construct design, the types of target cells, the vector type 
and dose, and the administration method. Transcriptional regulatory elements, 
for instance, promoters and enhancers, are essential vector components for 
optimization of transgene expression. It has been shown that the PGK promoter 
leads to moderate transgene expression, both in vitro (19, 20) and in vivo (21). 
Lentiviral vector with EF-1α was shown to lead to higher transgene expression 
than that with PGK (22). However, the effects of different promoters on transgene 
expression are still not well elucidated, due to the variety of lentiviral vectors 
used in studies and lack of direct comparison of promoters and transgene 
expression. Moreover, the use of WPRE is often important for transgene 
expression and titers of therapeutic vectors (23-25). However, the enhancing 
ability of WPRE depends on the types of target cells, the type of viral vector 
context and its sequence (26-29). WHV X protein is a transcriptional activator 
implicated in the development of liver tumors (30), which raises the safety 
concern about usage of WPRE in vectors for gene therapy. Herein, we designed 
constructs with full-length WPRE, mutated WPRE, truncated WPRE and without 
WPRE for a side-by-side comparison.  
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Our results show that 1) codon optimization significantly increased IDUA 
transgene expression; 2) compared with PGK promoter, EF-1α and CLP can 
achieve significantly higher transgene expression; 3) WPRE did not significantly 
enhance transgene expression. Further, based on the in vitro results, CEFoID, 
among the 10 constructs tested in this study, may be the most suitable construct 
for a clinical trial of lentiviral gene therapy for MPS I. These observations are yet 
to be further confirmed in a MPS I mouse model.  
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Figure 11. Construct information of 10 lentiviral vectors. oIDUA stands for 
codon optimized version of IDUA cDNA sequence. PGK: phosphoglycerate 
kinase 1 promoter; EF-1α: elongation factor 1-alpha promoter; IDUA: IDUA cDNA; 
oIDUA: codon optimized IDUA cDNA; WPRE: WHV posttranscriptional response 
element; WPRE*: mutated WPRE; short WPRE*: truncated WPRE by deleting 
alpha and beta subelements. 
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Figure 12. IDUA enzyme levels in cell lysates after transfection of lentiviral 
plasmids. HEK 293FT cells with no plasmids had IDUA enzyme activity of 0.97 ± 
0.34 nmol/h/mg protein. 
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Figure 13. IDUA enzyme levels in supernatants after transfection of 
lentiviral plasmids. IDUA enzyme activity in HEK 293 FT cells with no plasmids 
is <0.01 nmol/h/mL, while IDUA enzyme activity in cultured medium without cells 
is 0. 
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Chapter 5 
 
Conclusions 
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In the efforts to treat MPS I, measurement of IDUA enzyme levels is an essential 
assessment, and is widely used in research, clinical diagnostic testing, and the 
regulatory evaluation of new therapies. However, lack of methodological 
uniformity in the lysosomal enzyme activity assay has raised concern from FDA 
reviewers. Specifically, the reaction temperature ranges from 22 to 37 ˚C, with 
the reaction time ranging from 1 to 17 hours. More importantly, substrate 
concentrations used in different labs vary greatly, from 25 μM to 1425 μM. 
Consequently, even the enzyme level of the same sample within the same 
research group varies greatly. We successfully applied Michaelis-Menten kinetics 
into IDUA enzyme assays. By adjustment of Michaelis-Menten equation, IDUA 
enzyme activity with different substrate concentrations can be converted into 
Vmax. Further, the optimal reaction temperature and time was identified for IDUA 
enzyme assays. In Chapter 2, an IDUA enzyme assay protocol with low cost, 
high accuracy and methodological standardization was proposed. Based on 
these results, a standard protocol for IDUA enzyme assay was established, 
which will not only benefit studies in MPS I disease, but also provides guidance 
for enzyme assays in other lysosomal diseases. 
 
Study in Chapter 3 for the first time demonstrated that repeated, high-dose ERT 
can provide not only metabolic correction but also neurological improvements. 
With 4 weekly 20 fold dose injections, IDUA levels were increased and GAG 
storage was reduced in brain cortex and cerebellum. More importantly, learning 
abnormality in MPS I mice was significantly reduced. These results provide proof 
of principle that with sufficient plasma IDUA levels, a small amount of enzyme 
can provide neurological benefits in adult affected animals. Although 
intraventricular (1) and intrathecal (2, 3) administration of enzyme or gene vector 
have produced neurological improvements, these strategies are of limited use by 
their invasive nature. In light of this, the optimal therapeutic strategy might be 
delivering enzyme uniformly to the CNS.  
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Previous study in our lab has already demonstrated the efficacy of a lentivital 
vector (CSP1) in MPS I mouse model. To further improve the efficacy of this 
lentiviral gene therapy, we designed 9 more constructs by codon optimization 
and different combinations of promoters and enhancers. Achieving higher IDUA 
transgene expression in MPS I mice with the same dose will remarkably increase 
the ease of producing sufficient vector for human clinical trials, and improve 
safety by virtue of reducing the total exposure to lentiviral vector and insertional 
events. In Chapter 4, we comparatively evaluated 10 lentiviral constructs by 
measuring IDUA enzyme activity following transfection into HEK 293FT cells. 
Based on IDUA levels in cell lysates and supernatants, 6 constructs were 
selected for virus production and in vivo confirmation in MPS I mice. Also, these 
results provided evidence for future design of lentiviral and other vectors. 
 
In theory, gene therapy is an ideal option for treating MPS diseases because a 
single injection can provide sustained IDUA expression and correction in both 
visceral organs and CNS. In spite of the high sustained enzyme expression, 
lentiviral and retroviral vectors are associated with safety concern about 
insertional mutagenesis. The main drawback of AAV and non-viral vectors may 
be that the episomal transgene expression cannot last for long. Recently, new 
genome editing methods, for instance, zinc finger nuclease (ZFN), transcription 
activator-like effector nucleases (TALENs) and CRISPRs (clustered regularly 
interspaced short palindromic repeats) emerged as promising strategies for gene 
therapy. These methods can create DNA double strand break (DSB) at specific 
sites. Through homology directed repair (HDR), a correct DNA sequence can be 
integrated and provide expression of therapeutic genes. The main advantage of 
these methods will be providing sustained transgene expression through 
integrated sequence and avoiding risk of insertional mutagenesis by specific 
sequence targeting. There are already some cutting-edge studies using these 
genome editing methods for gene therapy: ZFN (4, 5), TALEN (6) and CRIPR (7-
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10). Currently, the main focus in this field is establishing successful delivery 
methods and eliminating off-target effects.   
 
Closing remarks 
Collectively, the results presented in this dissertation provide preclinical data 
supporting the design of a clinical trial to test intravenous administration of 
lentiviral vector in MPS I patients. This strategy could further be applied for the 
treatment of other lysosomal storage diseases and neurological disorders in 
which widespread distribution of a gene product is necessary. 
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